



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2022





© 2022 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

August 2022

N = 7501



Health Authority	Male	Female	All
FRASER	1467	450	1917
INTERIOR	449	114	563
NORTHERN	144	81	225
VANCOUVER COASTAL	3337	446	3783
VANCOUVER ISLAND	817	163	980
	<b>6214</b>	<b>1254</b>	<b>7468</b>
		<b>Unknown/not stated:</b>	<b>33</b>
		<b>Total:</b>	<b>7501</b>

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2017 - August 2022)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2017 - August 2022)



**Notes:**


Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month








### 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (August 2017 - August 2022)






### 1.5 BC-CfE Enrolment: New Antiretroviral Participants (August 2017 - August 2022)






1.6 Percent Distribution of Active Participants by CD4 Count (August 2017 - August 2022)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(August 2017 - August 2022)






### 1.8 Active and Inactive Participants (August 2017 - August 2022)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2017 - August 2022)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2017 - August 2022)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(August 2017 - August 2022)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (August 2017 - August 2022)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2017 - August 2022)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2017 - August 2022)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2017 - August 2022)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2017 - August 2022)






1.17 Distribution of Participants on Entry/Integrase Inhibitors  
at the time of first ARV Therapy by INGREDIENT

(August 2017 - August 2022)






1.18 Baseline CD4 for Antiretroviral First Starts (August 2017 - August 2022)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (August 2017 - August 2022)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (August 2017 - August 2022)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2017 - August 2022)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	30	4	0	4	1	840	4	<40	4
1988	31	5	0	5	3	340	5	<40	3
1989	29	49	1	50	26	505	48	<40	3
1990	28	54	1	55	32	525	55	<40	3
1991	28	37	2	39	18	555	36	<40	3
1992	28	55	5	60	22	630	57	<40	3
1993	27	124	14	138	82	515	134	<40	3
1994	25	67	13	80	47	490	73	<40	3
1995	25	125	20	145	87	490	134	<40	3
1996	24	307	48	355	207	570	331	<40	3
1997	21	259	34	293	175	620	273	<40	3
1998	21	186	42	228	137	540	201	<40	3
1999	21	147	38	185	114	595	159	<40	3
2000	21	117	31	148	94	615	137	<40	3
2001	20	112	22	134	81	530	124	<40	3
2002	19	119	25	144	97	570	137	<40	3
2003	19	132	24	156	105	630	146	<40	3
2004	18	148	34	182	111	600	160	<40	3
2005	17	174	39	213	139	620	197	<40	3
2006	16	168	41	209	128	615	190	<40	3
2007	15	221	43	264	163	670	236	<40	3
2008	14	274	60	334	217	640	304	<40	3
2009	13	292	65	357	224	615	320	<40	3
2010	12	253	66	319	215	670	297	<40	3
2011	11	314	72	386	243	710	343	<40	3
2012	10	256	60	316	205	710	293	<40	3
2013	9	245	67	312	203	700	277	<40	3
2014	8	275	48	323	191	740	292	<40	3
2015	7	268	42	310	202	680	276	<40	3
2016	6	246	49	295	187	700	255	<40	3
2017	5	213	33	246	160	680	221	<40	3
2018	4	186	53	239	159	730	217	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	3	228	42	270	194	660	247	<40	3
2020	2	182	53	235	173	690	207	<40	3
2021	1	201	35	236	153	591	221	<40	3
2022	0	182	33	215	178	580	204	<40	3
<b>Total:</b>		<b>6225</b>	<b>1255</b>	<b>7480</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	7385	745	1942	<40	1393	630
FEB-2021	7378	748	1787	<40	1276	630
MAR-2021	7433	743	2015	<40	1429	620
APR-2021	7417	746	1828	<40	1324	636
MAY-2021	7452	742	1868	<40	1306	630
JUN-2021	7456	738	1880	<40	1355	610
JUL-2021	7460	744	1820	<40	1348	640
AUG-2021	7465	741	1981	<40	1354	630
SEP-2021	7432	750	1763	<40	1248	630
OCT-2021	7432	755	1855	<40	1292	630
NOV-2021	7446	750	2021	<40	1379	630
DEC-2021	7462	757	1543	<40	1043	630
JAN-2022	7465	756	1878	<40	1316	650
FEB-2022	7386	774	1803	<40	1258	620
MAR-2022	7458	766	1904	<40	1246	620
APR-2022	7420	778	1755	<40	1145	620
MAY-2022	7477	763	1998	<40	1300	620
JUN-2022	7483	759	1839	<40	1182	630
JUL-2022	7498	755	1762	<40	1127	645
AUG-2022	7501	758	1990	<40	1196	620

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	773	196	73	<40	56	525
FEB-2021	785	196	69	<40	56	510
MAR-2021	769	247	89	<40	71	630
APR-2021	803	255	73	<40	58	615
MAY-2021	781	270	73	<40	66	540
JUN-2021	779	262	65	57	49	540
JUL-2021	780	274	52	102	37	530
AUG-2021	786	263	53	<40	44	625
SEP-2021	829	227	64	<40	41	610
OCT-2021	832	240	79	<40	60	540
NOV-2021	816	263	78	<40	61	450
DEC-2021	796	248	48	<40	32	385
JAN-2022	788	273	55	<40	43	610
FEB-2022	858	233	73	<40	55	620
MAR-2022	802	285	94	<40	73	517
APR-2022	838	279	70	<40	53	550
MAY-2022	779	339	60	<40	43	490
JUN-2022	781	330	61	<40	43	400
JUL-2022	783	314	60	<50	32	460
AUG-2022	802	292	59	78	44	550

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2021	7359	773	14	9	205	159	37	14210
FEB-2021	7352	785	15	13	186	189	-7	14234
MAR-2021	7405	769	15	24	203	156	53	14271
APR-2021	7390	803	13	9	165	173	-15	14296
MAY-2021	7418	781	14	14	177	143	28	14325
JUN-2021	7435	779	7	15	186	174	17	14351
JUL-2021	7438	780	9	12	170	166	3	14371
AUG-2021	7436	786	16	12	174	167	-2	14393
SEP-2021	7400	829	14	9	174	199	-36	14423
OCT-2021	7393	832	17	6	186	174	-7	14446
NOV-2021	7418	816	11	15	199	175	25	14472
DEC-2021	7431	796	22	6	204	174	13	14490
JAN-2022	7433	788	19	7	161	144	2	14505
FEB-2022	7374	858	8	9	151	211	-59	14530
MAR-2022	7435	802	16	9	232	160	61	14559
APR-2022	7400	838	11	1	156	179	-35	14579
MAY-2022	7453	779	13	13	205	146	53	14603
JUN-2022	7462	781	11	15	178	169	9	14640
JUL-2022	7476	783	10	14	187	174	14	14679
AUG-2022	7480	802	15	19	169	169	4	14718

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2021	205	6681	452	46	<b>7384</b>	2.78%	90.48%	6.12%	0.62%	<b>100.00%</b>
FEB-2021	226	6653	448	51	<b>7378</b>	3.06%	90.17%	6.07%	0.69%	<b>100.00%</b>
MAR-2021	249	6670	463	51	<b>7433</b>	3.35%	89.73%	6.23%	0.69%	<b>100.00%</b>
APR-2021	275	6644	454	44	<b>7417</b>	3.71%	89.58%	6.12%	0.59%	<b>100.00%</b>
MAY-2021	299	6640	465	48	<b>7452</b>	4.01%	89.10%	6.24%	0.64%	<b>100.00%</b>
JUN-2021	326	6613	471	46	<b>7456</b>	4.37%	88.69%	6.32%	0.62%	<b>100.00%</b>
JUL-2021	354	6590	470	46	<b>7460</b>	4.75%	88.34%	6.30%	0.62%	<b>100.00%</b>
AUG-2021	381	6571	471	42	<b>7465</b>	5.10%	88.02%	6.31%	0.56%	<b>100.00%</b>
SEP-2021	398	6525	462	47	<b>7432</b>	5.36%	87.80%	6.22%	0.63%	<b>100.00%</b>
OCT-2021	409	6517	460	46	<b>7432</b>	5.50%	87.69%	6.19%	0.62%	<b>100.00%</b>
NOV-2021	438	6508	457	43	<b>7446</b>	5.88%	87.40%	6.14%	0.58%	<b>100.00%</b>
DEC-2021	468	6492	457	45	<b>7462</b>	6.27%	87.00%	6.12%	0.60%	<b>100.00%</b>
JAN-2022	499	6468	455	43	<b>7465</b>	6.68%	86.64%	6.10%	0.58%	<b>100.00%</b>
FEB-2022	525	6371	445	45	<b>7386</b>	7.11%	86.26%	6.02%	0.61%	<b>100.00%</b>
MAR-2022	550	6408	455	45	<b>7458</b>	7.37%	85.92%	6.10%	0.60%	<b>100.00%</b>
APR-2022	567	6357	450	46	<b>7420</b>	7.64%	85.67%	6.06%	0.62%	<b>100.00%</b>
MAY-2022	597	6381	452	47	<b>7477</b>	7.98%	85.34%	6.05%	0.63%	<b>100.00%</b>
JUN-2022	614	6377	450	42	<b>7483</b>	8.21%	85.22%	6.01%	0.56%	<b>100.00%</b>
JUL-2022	634	6374	445	45	<b>7498</b>	8.46%	85.01%	5.93%	0.60%	<b>100.00%</b>
AUG-2022	643	6373	442	43	<b>7501</b>	8.57%	84.96%	5.89%	0.57%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	12 60%	2220 31%	6 30%	1963 27%	18 90%	4046 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	16 67%	2298 32%	6 25%	1900 26%	22 92%	4062 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	23 62%	2368 33%	6 16%	1859 26%	29 78%	4112 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	15 52%	2497 34%	10 34%	1759 24%	22 76%	4131 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	17 65%	2574 35%	5 19%	1698 23%	22 85%	4153 57%
JUL-2021	3 15%	3126 43%	2 10%	2707 37%	0 0%	23 0%	13 65%	2626 36%	4 20%	1655 23%	17 85%	4166 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 37%	0 0%	23 0%	16 73%	2660 36%	5 23%	1631 22%	21 95%	4182 57%
SEP-2021	4 13%	3078 42%	2 7%	2614 36%	1 3%	22 0%	21 70%	2707 37%	5 17%	1587 22%	26 87%	4178 57%
OCT-2021	5 22%	3082 42%	5 22%	2591 36%	0 0%	20 0%	13 57%	2755 38%	5 22%	1563 21%	18 78%	4196 58%
NOV-2021	3 12%	3071 42%	2 8%	2552 35%	0 0%	19 0%	18 72%	2812 39%	4 16%	1534 21%	22 88%	4216 58%
DEC-2021	3 18%	3067 42%	1 6%	2514 34%	0 0%	19 0%	10 59%	2861 39%	5 29%	1503 21%	14 82%	4237 58%
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3200 44%	4 11%	1237 17%	31 86%	4321 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3232 44%	9 23%	1218 17%	35 90%	4346 59%
AUG-2022	5 13%	2992 41%	4 11%	2262 31%	0 0%	18 0%	30 79%	3278 45%	3 8%	1179 16%	33 87%	4361 59%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	1 0%	0 0%	656 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	644 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	622 32%	3 75%	1261 64%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	547 30%	2 100%	1205 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1184 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	515 29%	3 100%	1183 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	508 29%	3 75%	1171 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1152 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1029 70%	0 0%	45 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	142 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	98 9%	3 75%	340 30%	0 0%	134 12%	0 0%	316 28%	1 25%	243 22%
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2111 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2150 40%	5 24%	2488 46%	1 5%	374 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2192 40%	5 20%	2470 46%	2 8%	366 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2234 41%	3 20%	2469 45%	1 7%	363 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2303 42%	4 18%	2459 45%	1 5%	348 6%	0 0%	24 0%	0 0%	392 7%
DEC-2021	8 57%	2348 42%	5 36%	2463 45%	1 7%	349 6%	0 0%	24 0%	0 0%	380 7%
JAN-2022	11 73%	2421 43%	2 13%	2468 44%	1 7%	347 6%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	6 29%	2437 44%	0 0%	331 6%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	3 11%	2460 43%	1 4%	324 6%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	5 26%	2436 43%	0 0%	312 5%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	5 23%	2455 43%	0 0%	309 5%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2711 47%	5 15%	2454 42%	0 0%	300 5%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2747 47%	7 20%	2452 42%	3 9%	298 5%	0 0%	22 0%	1 3%	342 6%
AUG-2022	27 77%	2796 48%	6 17%	2453 42%	1 3%	295 5%	1 3%	22 0%	1 3%	340 6%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1233	16.71	894	12.12	4226	57.28	223	3.02	689	9.34	113	1.53
MAR-2021	1210	16.28	890	11.97	4274	57.50	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4383	58.75	352	4.72	702	9.41	99	1.33
AUG-2021	1090	14.60	817	10.94	4384	58.73	377	5.05	700	9.38	97	1.30
SEP-2021	1070	14.40	812	10.93	4370	58.80	394	5.30	694	9.34	92	1.24
OCT-2021	1053	14.17	809	10.89	4387	59.03	406	5.46	685	9.22	92	1.24
NOV-2021	1038	13.94	804	10.80	4396	59.04	435	5.84	682	9.16	91	1.22
DEC-2021	1020	13.67	790	10.59	4416	59.18	464	6.22	682	9.14	90	1.21
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4559	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4581	61.10	632	8.43	654	8.72	76	1.01
AUG-2022	829	11.05	691	9.21	4617	61.55	641	8.55	649	8.65	74	0.99

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	3	2	2	3	210
DEC-2021	6	1	1	1	3	0	350
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	14	1	4	3	2	2	225
AUG-2022	19	1	3	3	4	5	380

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2021	12395	3844
FEB-2021	12388	3839
MAR-2021	12387	3829
APR-2021	12376	3816
MAY-2021	12371	3804
JUN-2021	12372	3798
JUL-2021	12393	3817
AUG-2021	12387	3823
SEP-2021	12356	3791
OCT-2021	12343	3783
NOV-2021	12346	3774
DEC-2021	12326	3768
JAN-2022	12312	3767
FEB-2022	12336	3782
MAR-2022	12365	3798
APR-2022	12395	3823
MAY-2022	12386	3812
JUN-2022	12401	3814
JUL-2022	12427	3823
AUG-2022	12448	3834

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved


**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7501  
Aug-2022

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2022

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2022

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2022

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2022

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2022

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>43</b>	<b>59</b>	<b>26</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>77</b>	<b>104</b>	<b>59</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>426</b>	<b>575</b>	<b>324</b>	
THOMPSON/CARIBOO/ SHUSWAP	20-34	22	22	13
	35-49	60	65	41
	50+	130	204	100
<b>Total HSDA:</b>	<b>212</b>	<b>291</b>	<b>154</b>	
<b>Total HA:</b>		<b>758</b>	<b>1029</b>	<b>563</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>758</b>	<b>1029</b>	<b>563</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	157	214	114
Male	601	815	449

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	563	56	640	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	22	12
	5 years or more	11	6
	<5 years	10	8
	<b>Total HSDA:</b>	<b>43</b>	<b>26</b>
KOOTENAY BOUNDARY	10 years or more	46	32
	5 years or more	16	13
	<5 years	15	14
	<b>Total HSDA:</b>	<b>77</b>	<b>59</b>
OKANAGAN	10 years or more	273	200
	5 years or more	84	64
	<5 years	69	60
	<b>Total HSDA:</b>	<b>426</b>	<b>324</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	135	104
	5 years or more	48	32
	<5 years	29	18
	<b>Total HSDA:</b>	<b>212</b>	<b>154</b>
<b>Total HA:</b>		<b>758</b>	<b>563</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	476	348
5 years or more	159	115
<5 years	123	100
<b>Total HA:</b>	<b>758</b>	<b>563</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	11	20
KOOTENAY BOUNDARY	77	136	26	49
OKANAGAN	234	1037	52	338
THOMPSON/CARIBOO/SHUSWAP	149	552	34	135
<b>Total:</b>	<b>511</b>	<b>1795</b>	<b>123</b>	<b>542</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>113</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	23
	35-49	96	100	60
	50+	253	352	190
	<b>Total HSDA:</b>		<b>388</b>	<b>493</b>
FRASER NORTH	20-34	117	117	76
	35-49	362	387	269
	50+	645	1013	490
	<b>Total HSDA:</b>		<b>1124</b>	<b>1517</b>
FRASER SOUTH	0-19	7	7	6
	20-34	99	101	72
	35-49	293	322	230
	50+	616	929	495
	<b>Total HSDA:</b>		<b>1015</b>	<b>1359</b>
<b>Total HA:</b>		<b>2527</b>	<b>3369</b>	<b>1917</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	12
	20-34	249	253	171
	35-49	751	809	559
	50+	1514	2294	1175
<b>Total HA:</b>		<b>2527</b>	<b>3369</b>	<b>1917</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	614	784	450
Male	1913	2585	1467

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1917	53	650	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	252	187
	5 years or more	70	43
	<5 years	66	49
	<b>Total HSDA:</b>	<b>388</b>	<b>279</b>
FRASER NORTH	10 years or more	700	500
	5 years or more	245	189
	<5 years	179	146
	<b>Total HSDA:</b>	<b>1124</b>	<b>835</b>
FRASER SOUTH	10 years or more	630	490
	5 years or more	225	173
	<5 years	160	140
	<b>Total HSDA:</b>	<b>1015</b>	<b>803</b>
<b>Total HA:</b>		<b>2527</b>	<b>1917</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1582	1177
	5 years or more	540	405
	<5 years	405	335
<b>Total HA:</b>		<b>2527</b>	<b>1917</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	144	523	29	57
FRASER NORTH	259	1599	43	220
FRASER SOUTH	225	1748	47	480
<b>Total:</b>	<b>628</b>	<b>3870</b>	<b>119</b>	<b>757</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	186
FRASER NORTH	703
FRASER SOUTH	459
<b>Total:</b>	<b>1348</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>357</b>	<b>523</b>
RICHMOND	20-34	30	31	17
	35-49	47	48	37
	50+	115	168	96
	<b>Total HSDA:</b>	<b>192</b>	<b>247</b>	<b>150</b>
VANCOUVER	0-19	12	12	11
	20-34	444	459	306
	35-49	1255	1398	885
	50+	2970	5237	2147
	<b>Total HSDA:</b>	<b>4681</b>	<b>7106</b>	<b>3349</b>
<b>Total HA:</b>		<b>5230</b>	<b>7876</b>	<b>3783</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	12
	20-34	504	520	343
	35-49	1383	1535	981
	50+	3330	5808	2447
<b>Total HA:</b>		<b>5230</b>	<b>7876</b>	<b>3783</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	602	958	446
Male	4626	6916	3337
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3783	55	650	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	238	187
	5 years or more	63	55
	<5 years	56	42
	<b>Total HSDA:</b>	<b>357</b>	<b>284</b>
RICHMOND	10 years or more	119	90
	5 years or more	33	24
	<5 years	40	36
	<b>Total HSDA:</b>	<b>192</b>	<b>150</b>
VANCOUVER	10 years or more	3196	2211
	5 years or more	860	630
	<5 years	625	508
	<b>Total HSDA:</b>	<b>4681</b>	<b>3349</b>
<b>Total HA:</b>		<b>5230</b>	<b>3783</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3553	2488
	5 years or more	956	709
	<5 years	721	586
<b>Total HA:</b>		<b>5230</b>	<b>3783</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	186	416	49	69
RICHMOND	46	306	9	89
VANCOUVER	667	11402	209	5386
<b>Total:</b>	<b>899</b>	<b>12124</b>	<b>267</b>	<b>5544</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>82</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>349</b>	<b>509</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>123</b>	<b>172</b>
SOUTH VANCOUVER ISLAND	20-34	74	80	54
	35-49	185	211	144
	50+	528	842	405
	<b>Total HSDA:</b>	<b>787</b>	<b>1133</b>	<b>603</b>
<b>Total HA:</b>		<b>1259</b>	<b>1814</b>	<b>980</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1259</b>	<b>1814</b>	<b>980</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	216	315	163
Male	1043	1499	817

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	980	56	590	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	209	170
	5 years or more	82	61
	<5 years	58	47
	<b>Total HSDA:</b>	<b>349</b>	<b>278</b>
NORTH VANCOUVER ISLAND	10 years or more	83	69
	5 years or more	29	20
	<5 years	11	10
	<b>Total HSDA:</b>	<b>123</b>	<b>99</b>
SOUTH VANCOUVER ISLAND	10 years or more	476	341
	5 years or more	163	135
	<5 years	148	127
	<b>Total HSDA:</b>	<b>787</b>	<b>603</b>
<b>Total HA:</b>		<b>1259</b>	<b>980</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	768	580
	5 years or more	274	216
	<5 years	217	184
<b>Total HA:</b>		<b>1259</b>	<b>980</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	201	916	74	194
NORTH VANCOUVER ISLAND	155	276	38	68
SOUTH VANCOUVER ISLAND	219	1908	38	580
<b>Total:</b>	<b>575</b>	<b>3100</b>	<b>150</b>	<b>842</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	95
NORTH VANCOUVER ISLAND	39
SOUTH VANCOUVER ISLAND	129
<b>Total:</b>	<b>263</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	5
	35-49	16	19	11
	50+	25	33	12
	<b>Total HSDA:</b>	<b>49</b>	<b>60</b>	<b>28</b>
NORTH WEST	20-34	*	6	*
	35-49	*	37	*
	50+	*	75	*
	<b>Total HSDA:</b>	<b>71</b>	<b>118</b>	<b>55</b>
NORTHERN INTERIOR	0-19	6	6	*
	20-34	21	22	*
	35-49	57	73	*
	50+	112	190	*
	<b>Total HSDA:</b>	<b>196</b>	<b>291</b>	<b>142</b>
<b>Total HA:</b>		<b>316</b>	<b>469</b>	<b>225</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	33	36	*
	35-49	96	129	*
	50+	181	298	*
<b>Total HA:</b>		<b>316</b>	<b>469</b>	<b>225</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	114	173	81
Male	202	296	144

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	225	53	570	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	5	*
	<5 years	14	*
	<b>Total HSDA:</b>	<b>49</b>	<b>28</b>
NORTH WEST	10 years or more	50	38
	5 years or more	11	9
	<5 years	10	8
	<b>Total HSDA:</b>	<b>71</b>	<b>55</b>
NORTHERN INTERIOR	10 years or more	100	76
	5 years or more	57	37
	<5 years	39	29
	<b>Total HSDA:</b>	<b>196</b>	<b>142</b>
<b>Total HA:</b>		<b>316</b>	<b>225</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	180	128
	5 years or more	73	49
	<5 years	63	48
<b>Total HA:</b>		<b>316</b>	<b>225</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	40	64	5	7
NORTH WEST	85	169	18	36
NORTHERN INTERIOR	121	495	22	193
<b>Total:</b>	<b>246</b>	<b>728</b>	<b>45</b>	<b>236</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	*
NORTH WEST	*
NORTHERN INTERIOR	*
<b>Total:</b>	<b>36</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	31	50	*
	THOMPSON/CARIBOO/SHUSWAP	28	52	*
	<b>Total HA:</b>	<b>70</b>	<b>122</b>	<b>49</b>
FRASER	FRASER EAST	35	48	25
	FRASER NORTH	52	92	42
	FRASER SOUTH	84	119	62
	<b>Total HA:</b>	<b>171</b>	<b>259</b>	<b>129</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	54	24
	RICHMOND	6	11	5
	VANCOUVER	466	901	373
	<b>Total HA:</b>	<b>500</b>	<b>966</b>	<b>402</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	79	34
	NORTH VANCOUVER ISLAND	15	27	12
	SOUTH VANCOUVER ISLAND	47	94	37
	<b>Total HA:</b>	<b>107</b>	<b>200</b>	<b>83</b>
NORTHERN	NORTH EAST	9	13	5
	NORTH WEST	30	65	24
	NORTHERN INTERIOR	68	114	55
	<b>Total HA:</b>	<b>107</b>	<b>192</b>	<b>84</b>
<b>Total:</b>		<b>955</b>	<b>1739</b>	<b>747</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	606	1116	476
Female	349	623	271

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	747	53	530	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir:** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Antiretroviral:** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla:** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Complera:** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Descovy:** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay):** an INTEGRASE INHIBITOR from ViiV Healthcare.





## Monthly Report

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir:** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine:** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa:** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine:** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





## Monthly Report

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**N(t)RTI:** a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Odefsey:** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix:** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.







## Monthly Report

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq:** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir:** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada:** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

